Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
"The progression of elecoglipron is an important step in delivering a differentiated weight management portfolio, offering monotherapies and combinations, designed to address the biological complexity of obesity and comorbidities that can be tailored to individual needs, enabling people to live healthier lives." Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca Weight Loss Results In AstraZeneca's VISTA Phase 2b trial , adults living with obesity or overweight plus at least one weight-related condition lost an average of 10.5% of their body weight after 26 weeks on the highest dose of elecoglipron
The association of metabolic syndrome and urolithiasis
It is safe and well-tolerated by most people, but medical advice is recommended for long-term use
According to a 2017 review published in the Journal of the American Medical Association ( JAMA) , prostate cancer is the most common health diagnosis in men, with over 160,000 new cases reported in the United States annually
Tirzepatide is approved for type 2 diabetes and weight management, not for alcohol
